BOLT News
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)PR NewswireNEW YORK, Oct. 26, 2026 NEW YORK, Oct. 26, 2026...
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)PR NewswireNEW YORK, Oct. 26, 2026 NEW YORK, Oct. 26, 2026...
PR Newswire
The Watchlist is Heating Up Again
The names on today’s watchlist may look familiar, but the stories are moving. NeOnc Technologies Holdings (NASDAQ:NTHI) is approaching an important FDA discussion, XIAO-I Corporation (NASDAQ:AIXI) remains a high-volatility AI stock, and BIO-key International (NASDAQ:BKYI) is adding government customers in the Gulf. Meanwhile, Bolt Biotherapeutics (NASDAQ:BOLT) announced a major acquisition and financing package, Nautilus Biotechnology (NASDAQ:NAUT) is preparing to report earnings, and AI OKTO (NASDAQ:AIOK) declared a substantial special dividend. Across communications technology with ClearOne (NASDAQ:CLRO), staffing and recruiting with Robert Half (NYSE:RHI), and satellite cybersecurity with WISeSat.Space (NASDAQ: SAIQ).
24-7 Market News
Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement
(RTTNews) - Friday, Bolt Biotherapeutics, Inc. (BOLT) announced its acquisition of Prana Therapies, Inc. through a stock-for-stock transaction aimed at advancing Prana's pipeline of half-life-extended multispecific antibodies developed using its proprietary INSPIRE platform...
Nasdaq News: Markets
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks